Venkata Kashyap Yellepeddi

Dr. Venkata Kashyap Yellepeddi

Associate Professor, Division of Clinical Pharmacology, School of Medicine, University of Utah, Salt Lake City, Utah, United States.
+1
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
VYVenkata Kashyap Yellepeddi
Venkata Kashyap Yellepeddi
SPSrinath Palakurthi
Srinath Palakurthi
Topical ocular drug delivery has been considered to be an ideal route of administration for treatment of ocular diseases related to the anterior segment of the eye. However, topical ocular delivery is a challenging task because of barriers such as nasolacrimal drainage, corneal epithelium, blood–ocular barriers, and metabolism in the eye. Approaches to improve ocular bioavailability include physical approaches such as formulations of drugs as solutions (Zymaxid™), suspensions (Zigran®), gels (Akten®) and chemical approaches such as prodrugs (Xalatan™), chemical delivery systems, and soft drugs. The purpose of this review article is to summarize recent advances in topical drug delivery to the anterior segment of the eye. Functional transporters in the corneal epithelium were also discussed as they provide prospects in topical ocular delivery. In addition to conventional delivery systems, novel delivery systems involving nanocarriers were also investigated for topical ocular delivery. Furthermore, due to increased interest, gene therapy applications of topical ocular delivery of genes to the anterior segment of the eye were also discussed. Research in topical ocular delivery is active for more than 50 years and proven to be advantageous for the treatment of many ocular diseases. However, there is scope for innovation in topical drug delivery to develop delivery systems with a high patient safety profile and compliance for effective clinical usefulness.

30 June 2009 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
VYVenkata Kashyap Yellepeddi
Venkata Kashyap Yellepeddi
AKAjay Kumar
Ajay Kumar
SPSrinath Palakurthi
Srinath Palakurthi
(2009). Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications. Expert Opinion on Drug Delivery: Vol. 6, No. 8, pp. 835-850. doi: 10.1517/17425240903061251

29 August 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Pradeep Kumar BollaPradeep Kumar Bolla
Pradeep Kumar Bolla
CMCarlos A. Meraz
Carlos A. Meraz
VRVictor A. Rodriguez
Victor A. Rodriguez
IDIsaac Deaguero
Isaac Deaguero
MSMahima Singh
Mahima Singh
Jwala RenukuntlaJwala Renukuntla
Jwala Renukuntla
Global incidence of superficial fungal infections caused by dermatophytes is high and affects around 40 million people. It is the fourth most common cause of infection. Clotrimazole, a broad spectrum imidazole antifungal agent is widely used to treat fungal infections. Conventional topical formulations of clotrimazole are intended to treat infections by effective penetration of drugs into the stratum corneum. However, drawbacks such as poor dermal bioavailability, poor penetration, and variable drug levels limit the efficiency. The present study aims to load clotrimazole into ufosomes and evaluate its topical bioavailability. Clotrimazole loaded ufosomes were prepared using cholesterol and sodium oleate by thin film hydration technique and evaluated for size, polydispersity index, and entrapment efficiency to obtain optimized formulation. Optimized formulation was characterized using scanning electron microscopy (SEM), X-ray diffraction (XRD), and differential scanning calorimetry (DSC). Skin diffusion studies and tape-stripping were performed using human skin to determine the amount of clotrimazole accumulated in different layers of the skin. Results showed that the optimized formulation had vesicle size <250 nm with ~84% entrapment efficiency. XRD and DSC confirmed the entrapment of clotrimazole into ufosomes. No permeation was observed through the skin up to 24 h following the permeation studies. Tape-stripping revealed that ufosomes led to accumulation of more clotrimazole in the skin compared to marketed formulation (Perrigo). Overall, results revealed the capability of ufosomes in improving the skin bioavailability of clotrimazole.

1 July 2015 in Drug Discovery Today
Verified
Journal Article
Open access
VYVenkata Kashyap Yellepeddi
Venkata Kashyap Yellepeddi
RSRavi Sheshala
Ravi Sheshala
HMHannah McMillan
Hannah McMillan
CGChirag Gujral
Chirag Gujral
DJDavid Jones
David Jones
TSThakur Raghu Raj Singh
Thakur Raghu Raj Singh
Punctal plugs (PPs) are miniature medical implants that were initially developed for the treatment of dry eyes. Since their introduction in 1975, many PPs made from different materials and designs have been developed. PPs, albeit generally successful, suffer from drawbacks such as epiphora and suppurative canaliculitis. To overcome these issues intelligent designs of PPs were proposed (e.g. SmartPLUG™ and Form Fit™). PPs are also gaining interest among pharmaceutical scientists for sustaining drug delivery to the eye. This review aims to provide an overview of PPs for dry eye treatment and drug delivery to treat a range of ocular diseases. It also discusses current challenges in using PPs for ocular diseases.

1 February 2008 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
DPDipak S. Pisal
Dipak S. Pisal
VYVenkata Kashyap Yellepeddi
Venkata Kashyap Yellepeddi
AKAjay Kumar
Ajay Kumar
RKRadhey S. Kaushik
Radhey S. Kaushik
MHMichael B. Hildreth
Michael B. Hildreth
SPSrinath Palakurthi
Srinath Palakurthi

1 November 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
VYVenkata Kashyap Yellepeddi
Venkata Kashyap Yellepeddi
AJAndrea Joseph
Andrea Joseph
ENElizabeth Nance
Elizabeth Nance